Apg Research — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$35,324	4
2024	Research	$12,687	6
2023	Research	$8,144	1

Breakdown

Who paid Research payments · program years 2023–2025

ACADIA Pharmaceuticals Inc $35,324 4 payments
Supernus Pharmaceuticals, Inc. $20,830 7 payments

Studies the money was for Research payments · program years 2023–2025

Acp-103-070 $21,813 3 payments
Acp-103-069 $13,511 1 payment
A Phase IV, Open-Label, Flexible-Dose Safety Trial Evaluating Spn-812 Administered With Psychostimulants in Children and Adolescents (6 to 17 Years of Age) With Disorder (Adhd) Attention-Deficit/Hyperactivity $10,573 2 payments
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Spn-812 Er for the Treatment of Pediatric Patients With Attention Deficit/Hyperactivity Disorder (Adhd) $8,144 1 payment
A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of SPN-812 in Preschool-Age Children (4 to 5 years old) with Attention-Deficit/Hyperactivity Disorder (ADHD) $2,114 4 payments

What the money was spent on Research payments · program years 2023–2025

Patient care $12,687 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.